Source-grounded facts extracted from NIKA PHARMACEUTICALS, INC's SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
NIKA PHARMACEUTICALS, INC engaged Boladale Lawal & Co (Chartered Accountants) as its auditor.
“On October 5, 2024, Nika Pharmaceuticals, Inc. engaged the firm of Boladale Lawal & Co (Chartered Accountants) to serve as the independent accountant to audit the company’s financial statements.”
NIKA PHARMACEUTICALS, INC dismissed OLAYINKA OYEBOLA & CO (Chartered Accountants) as its auditor.
“nder the Exchange Act (17 CFR 240.13e -4(c)) Section 4 - Matters Related to Accountants and Financial Statements Item 4.01 Changes in Registrant’s Certifying Accountant. On October 2, 2024, Nika Pharmaceuticals, Inc. made a discovery, which led it to consider that it is in the best interest not to continue its engagement of independent accountant OLAYINKA OYEBOLA & CO (Chartered Accountants). No services had been performed by OLAYINKA OYEBOLA & CO (Chartered Accountants) prior to the termination of the engagement on October 2, 2024. On October 5, 2024, Nika Pharmaceuticals, Inc.”
NIKA PHARMACEUTICALS, INC completed a disposition involving Dimitar Slavchev Savov (closed 2024-08-23).
“The procedure to return the 100% to Dimitar Slavchev Savov, who is an officer and director of Nika Pharmaceluticals, Inc. and general manager of Nika Pharmaceuticals, Ltd., was initiated on August 19, 2024 and was made effective on August 23, 2024, resulting in Nika Pharmaceuticals, Ltd. no longer being a wholly owned subsidiary of Nika Pharmaceuticals, Inc.”
NIKA PHARMACEUTICALS, INC completed an acquisition involving Dimitar Slavchev Savov for nominal value of the capital of the company, 5,000 BGN (closed 2024-05-09).
“Effective May 9, 2024, Nika Pharmaceuticals, Inc. acquired 100% of Nika Pharmaceuticals, Ltd., a limited liability company registered in Bulgaria with UIC: 175420503. The ownership was acquired from Dimitar SlavchevSavov who is an officer, director and majority shareholder of Nika Pharmaceuticals, Inc. and general manager of Nika Pharmaceuticals, Ltd. for the nominal value of the capital of the company, 5,000 BGN.”
NIKA PHARMACEUTICALS, INC completed an acquisition involving Alliance for Intellectual Property in the Field of Pharmacy, Chemistry, and Biology for 45,000 BGN (equivalent to around 24,683 USD).
“a dietary supplement. The technologies were purchased from Alliance for Intellectual Property in the Field of Pharmacy, Chemistry, and Biology (“AIPFPCB”) for a total price of 45,000 BGN (equivalent to around 24,683 USD) that was paid by Dimitar Slavchev Savov who is an officer and director of Nika Pharmaceuticals, Inc. and the general manager of Nika”
NIKA PHARMACEUTICALS, INC completed an acquisition involving Nika BioTechnology, Inc. (closed 2024-04-10).
“Pursuant to the terms of the merger of Nika BioTechnology, Inc. into Nika Pharmaceuticals, Inc., Nika Pharmaceuticals, Inc. has acquired the 40% stake in Nika Europe Ltd. that was owned by Nika BioTechnonoly, Inc.”
NIKA PHARMACEUTICALS, INC: Increased authorized Preferred A stock from 10,000,000 to 15,000,000 (effective 2024-03-04).
“Pursuant to the terms of the Agreement and Plan of Merger and the approval of the company’s board of directors and shareholders, Nika Pharmaceuticals, Inc. has filed an Amendment to the Articles of Incorporation to increase the number of authorized Preferred A stock from 10,000,000 to 15,000,000, effective as of March 4, 2024 when the amendment was filed with the Colorado Secretary of State.”
NIKA PHARMACEUTICALS, INC engaged Fruci & Associates II, PLLC as its auditor.
“On February 14, 2024, Nika Pharmaceuticals, Inc. engaged the firm of Fruci & Associates II, PLLC to serve as the independent accountant to audit the company’s financial statements.”
NIKA PHARMACEUTICALS, INC dismissed B F Borgers CPA PC as its auditor.
“PA PC on February 14, 2024 and engage Fruci & Associates II, PLLC. The members of the board of directors have discussed the issue with the former”
NIKA PHARMACEUTICALS, INC underwent a change of control involving Dimitar Slavchev Savov for $140,000 (closed 2022-04-01).
“As a result of the purchase by Dimitar Slavchev Savov of a total of 11,489,000 (87%) shares of common stock of the Company from the Company’s former President and CEO, Mr. Phil E. Ray and certain other shareholders for $140,000, a change in control of the Company occurred as of April 1, 2022.”
Dr. Darena Stoykova Zlateva was appointed as Chief Scientific Officer at NIKA PHARMACEUTICALS, INC.
“On November 12, 2022, Nika Pharmaceuticals, Inc. (the “company”) appointed Dr. Darena Stoykova Zlateva as the company’s Chief Scientific Officer (“CSO”).”
NIKA PHARMACEUTICALS, INC engaged BF Borgers CPA, PC as its auditor.
“On October24, 2022, Nika Pharmaceuticals, Inc. engaged the firm of BF Borgers CPA, PC to serve as the independent accountant to audit the company’s financial statements”
NIKA PHARMACEUTICALS, INC dismissed Pinnacle Accountancy Group of Utah as its auditor.
“board of directors deemed it in the best interests of the company to dismiss independent accountant Pinnacle Accountancy Group of UtahAugust 18, 2022”
Clifford Redekop was appointed as Secretary at NIKA PHARMACEUTICALS, INC.
“On April 1, 2022, the board of directors accepted the resignations of Mr. Phil E. Ray and Mrs. A. Terry Ray and appointed Dimitar Slavchev Savov to serve as President, CEO, CFO and Clifford Redekop to serve as Secretary of the Corporation.”
Clifford Redekop was appointed as Director at NIKA PHARMACEUTICALS, INC.
“Effective as of March 31, 2022, the board of directors appointed Dimitar Slavchev Savov, and Clifford Redekop to serve as the Registrant’s Directors.”
Dimitar Slavchev Savov was appointed as President, Chief Executive Officer, Chief Financial Officer at NIKA PHARMACEUTICALS, INC.
“On April 1, 2022, the board of directors accepted the resignations of Mr. Phil E. Ray and Mrs. A. Terry Ray and appointed Dimitar Slavchev Savov to serve as President, CEO, CFO and Clifford Redekop to serve as Secretary of the Corporation.”
Dimitar Slavchev Savov was appointed as Director at NIKA PHARMACEUTICALS, INC.
“Effective as of March 31, 2022, the board of directors appointed Dimitar Slavchev Savov, and Clifford Redekop to serve as the Registrant’s Directors.”
A. Terry Ray resigned as Director and Secretary at NIKA PHARMACEUTICALS, INC.
“On March 31, 2022, Mrs. A. Terry. Ray resigned his position as a Director and Secretary of Centennial Growth Equities, Inc. (the “Registrant”).”
Phil E. Ray resigned as Director, President and Chief Executive Officer at NIKA PHARMACEUTICALS, INC.
“On March 31, 2022, Mr. Phil E. Ray resigned his position as a Director, President and Chief Executive Officer of Centennial Growth Equities, Inc. (the “Registrant ”).”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.